Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Revvity Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while Revvity Inc trades at $106.58 (market cap $11.87B). The key difference: Revvity Inc pays a 0.26% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals.
| JPIN | RVTY | |
|---|---|---|
52-Week High | $76.96 | $117.75 |
52-Week Low | $63.14 | $82.26 |
Market Cap | — | $11.87B |
Sector | — | Technology |
Enterprise Value | — | $14.36B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
